How HRSA’s Rebate Model Pilot Program Could Destroy 340B
Has your health system prepared for HRSA’s forthcoming 340B Rebate Model Pilot Program, scheduled to begin January 1, 2026? We […]
340B, Blog, VytlOne
340B, Blog, VytlOne
Bausch Has Pulled Its Drug Catalog From The 340B Program.
What Bausch’s exit from the 340B program means for hospitals and patients. It would not be an exaggeration to say
340B, Blog, VytlOne
The Holistic Pharmacy Approach To 340B Patient Support
How to make Pharmacy “The Easy Part” of the patient experience. Anyone who’s ever been a hospital patient, or patient
340B, Blog, VytlOne
Optimize 340B Program Savings & Compliance With Data Mining
Since late 2019, VytlOne has supported the 340B programs of 33 health systems and 38 health centers. Altogether, we’ve generated
340B, Blog
Why A 340B Hospital Should Own A Specialty Pharmacy. Why Not.
Before we begin, we’re going to be honest with you. A significant component of VytlOne’s business is guiding 340B health
340B, Blog, VytlOne
How One Clinical Pharmacist Can Impact Hospital Readmissions
There are so many reasons Brandi Henneman has had such a positive impact on participation rates for VytlOne’s Readmission Reduction
340B, Blog
Overcome 340B Restrictions With Analytics And Human Insight
POST OUTLINE PHASE ONE: Organizing 340B data, coordinating teams Connecting and educating 340B system providers Requalifying all eligible, but unreimbursed, 340B
Blog
VytlOne To Build Specialty Pharmacy For Conway Medical Center
For Immediate Release Contact:Michael Jones205-706-2586 | [email protected] BIRMINGHAM, AL July 31, 2024 — South Carolina’s Conway Medical Center (CMC), a
340B, Blog
How Recent 340B Changes Impact Specialty Pharmacies In 2025
The evolving legal and legislative landscape surrounding the 340B Drug Pricing Program has significant implications for hospitals’ specialty pharmacies. Here’s
340B, Blog
The Case for Onsite Specialty Pharmacies in 340B Hospitals
Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications